Bioavailability

Bioavailability is a pharmacological term that describes the proportion of an administered substance that reaches systemic circulation or, more broadly, the fraction that arrives at its biological target in an active, usable form ^[2]. In the context of skincare and dermatology, bioavailability specifically refers to how much of a topically applied or injected active ingredient actually reaches the relevant skin cells — fibroblasts in the dermis, keratinocytes in the epidermis, or other target cell populations — in sufficient concentration to exert its intended biological effect.

Definition

In classical pharmacology, bioavailability is defined as the fraction of an administered dose that reaches systemic circulation unchanged ^[2]. An intravenous injection, by definition, has 100% bioavailability because the entire dose enters the bloodstream directly. For any other route of administration — oral, topical, intradermal — bioavailability is expressed as a percentage relative to IV administration.

For dermatological applications, the concept is adapted slightly: rather than systemic circulation being the reference point, the target is typically the dermis or epidermis. Dermal bioavailability refers to the fraction of an applied substance that successfully traverses the skin's barrier layers to reach its site of action in the skin itself ^[1][2].

The Skin Barrier Problem

The skin's primary function is to keep things out. The stratum corneum — the outermost layer of the epidermis, approximately 10-20 micrometers thick — is an extraordinarily effective barrier composed of flattened, dead keratinocytes (corneocytes) embedded in a lipid matrix arranged in lamellar bilayers ^[5]. This structure has been described as a "brick and mortar" architecture, where the corneocytes are the bricks and the intercellular lipids (ceramides, cholesterol, free fatty acids) are the mortar ^[5].

The 500 Dalton Rule

One of the most widely cited principles in transdermal drug delivery is the 500 Dalton rule, proposed by Bos and Meinardi in 2000 ^[1]. This empirical observation states that molecules with a molecular weight greater than 500 Daltons (Da) have extremely limited ability to passively penetrate the stratum corneum. Most successful topical drugs — retinoids, corticosteroids, vitamin C — have molecular weights well below this threshold.

This rule has profound implications for PDRN. Intact PDRN polymers have molecular weights ranging from 50,000 to 1,500,000 Da — orders of magnitude above the 500 Da cutoff ^[3]. Even the smallest PDRN oligonucleotide fragments (8-10 nucleotides long) have molecular weights of approximately 2,500-3,000 Da. This means that intact PDRN chains cannot passively diffuse through the stratum corneum by conventional transcellular or intercellular routes.

However, the 500 Dalton rule describes passive diffusion through intact skin under standard conditions. Several factors can modify or circumvent this barrier, which is precisely why formulation science and delivery methods are so important for PDRN products.

PDRN Delivery Routes and Their Bioavailability

Injectable PDRN (Highest Bioavailability)

Intradermal injection via mesotherapy technique delivers PDRN directly into the dermis, bypassing the stratum corneum entirely ^[3][4]. This achieves near-100% local bioavailability — essentially all of the injected PDRN reaches the dermal tissue where fibroblasts, the primary target cells, reside.

Products like Rejuran Healer (concentration: 0.2% PDRN in a hyaluronic acid gel vehicle) are designed specifically for this delivery route. The gel formulation creates a sustained-release depot in the dermis, where PDRN is gradually degraded by nucleases and the resulting nucleotides and adenosine exert their biological effects over days to weeks ^[3].

Injectable PDRN is the gold standard for bioavailability and the format supported by the strongest clinical evidence. However, it requires a medical professional, involves injection discomfort, and has a higher cost per treatment session.

Topical PDRN (Variable Bioavailability)

Topical PDRN products — serums, creams, ampoules, and masks — face the fundamental challenge of the stratum corneum barrier. The bioavailability of topically applied PDRN is significantly lower than injectable forms, but it is not zero ^[2].

Several mechanisms allow some degree of PDRN penetration through topical application:

• Appendageal pathway — Hair follicles and sweat glands create natural channels that bypass the stratum corneum. These shunt routes can allow larger molecules to reach the dermis, particularly in areas with high follicular density (face, scalp).
• Degradation products — As PDRN sits on the skin surface, endogenous skin nucleases can begin breaking it down into smaller fragments, nucleosides, and free bases. These smaller degradation products (molecular weight < 500 Da for free nucleosides: deoxyadenosine = 251 Da, thymidine = 242 Da) can penetrate the stratum corneum by conventional diffusion.
• Compromised barrier — After procedures such as microneedling, laser treatments, or chemical peels, the stratum corneum is disrupted, temporarily increasing permeability to larger molecules. Applying PDRN serum post-procedure takes advantage of this enhanced penetration window.

Microneedling-Assisted PDRN (Enhanced Bioavailability)

Microneedling creates thousands of temporary microchannels in the stratum corneum, dramatically increasing the bioavailability of topically applied substances ^[2]. When PDRN serum is applied during or immediately after microneedling, the microchannels (typically 0.25-1.5 mm deep) allow PDRN fragments to bypass the stratum corneum and reach the viable epidermis and upper dermis.

This combination approach achieves bioavailability intermediate between pure topical application and injectable delivery. It has the added benefit of the microneedling procedure itself triggering a wound healing cascade that synergizes with PDRN's regenerative mechanisms.

Factors Affecting Topical PDRN Bioavailability

Molecular Weight Distribution

Not all PDRN products contain the same distribution of fragment sizes. Products with a higher proportion of lower molecular weight fragments (50-100 kDa range) may achieve better topical penetration than those with predominantly high molecular weight chains (500-1500 kDa) ^[3]. Some manufacturers deliberately optimize the fragmentation process to produce a molecular weight profile that balances biological activity (which requires chains long enough for A2A receptor activation) with skin penetration potential.

Vehicle Formulation

The base formulation surrounding PDRN significantly affects its delivery efficiency ^[2]:

• Hyaluronic acid gels — HA creates a hydrated reservoir on the skin surface that maintains PDRN in solution and prolongs contact time with the stratum corneum.
• Liposomal encapsulation — Lipid vesicles can encapsulate PDRN fragments and fuse with the lipid matrix of the stratum corneum, facilitating transport.
• Penetration enhancers — Ingredients such as propylene glycol, ethanol, oleic acid, or certain surfactants temporarily disrupt the lamellar lipid organization of the stratum corneum, increasing permeability.
• Niacinamide co-formulation — Niacinamide (vitamin B3) has been shown to improve the penetration of co-formulated active ingredients while providing its own skin barrier benefits.

Application Conditions

Bioavailability can also be affected by how a topical PDRN product is applied:

• Occlusion — Covering the skin after application (with a sheet mask or occlusive layer) increases hydration of the stratum corneum, swelling the corneocytes and expanding the intercellular spaces, which improves penetration.
• Skin preparation — Gentle exfoliation before application removes the outermost layers of dead stratum corneum, reducing barrier thickness.
• Application site — Bioavailability varies by body location. Facial skin (thinner stratum corneum, high follicular density) has significantly higher permeability than trunk or limb skin.

Clinical Significance

Understanding bioavailability is essential for setting realistic expectations about PDRN products and choosing the right delivery method for individual goals ^[3][4]:

• Injectable PDRN delivers the highest bioavailability and is supported by the most clinical evidence. It is the appropriate choice for patients seeking maximal regenerative effect, particularly for specific concerns like scarring, deep wrinkle improvement, or significant skin quality restoration.
• Topical PDRN provides lower but meaningful bioavailability, particularly when formulated with penetration-enhancing vehicles and applied under occlusion or post-procedure. It is best suited for maintenance between injectable sessions, daily skin quality support, and patients who prefer non-invasive routines.
• Combination approaches — using topical PDRN after microneedling or in between injectable PDRN sessions — leverage the strengths of each delivery method to optimize cumulative bioavailability over time.

Key Takeaways

Bioavailability determines whether a PDRN product's active ingredient actually reaches the cells it needs to affect. Injectable PDRN achieves near-complete dermal bioavailability by bypassing the skin barrier entirely, while topical PDRN relies on appendageal pathways, surface degradation to smaller penetrable fragments, formulation technology, and barrier disruption techniques. Neither format is inherently superior — they serve different use cases. The most effective PDRN regimens often combine both injectable and topical delivery to maximize total bioavailability and maintain continuous regenerative stimulus to the skin.